ArticleInternational journal of endocrinology2014
Taurine alleviates the progression of diabetic nephropathy in type 2 diabetic rat model.
Article in International journal of endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Untangling amino acid metabolism in renal diseases: mechanisms, dysregulation, and critical gaps.Clinical kidney journal · 2026Review
- Effects ofFrontiers in immunology · 2026Article
- Effects of High Glucose Concentrations on PC12 Cells: Possible Implications on Neurodegeneration.Current issues in molecular biology · 2025Article
- Effects of a Diabetic Microenvironment on Neurodegeneration: Special Focus on Neurological Cells.Brain sciences · 2024Review
- The renoprotective effects of taurine against diabetic nephropathy via the p38 MAPK and TGF-β/Smad2/3 signaling pathways.Amino acids · 2023Article
- Taurine, Coenzyme QHearing research · 2023Review
- Article
- Urinary Metabolomic Profiling in Streptozotocin-Induced Diabetic Mice after Treatment with Losartan.International journal of molecular sciences · 2020Article
- Serum and urine metabolomics reveal potential biomarkers of T2DM patients with nephropathy.Annals of translational medicine · 2020Article
- Analysis of serum metabolomics among biopsy-proven diabetic nephropathy, type 2 diabetes mellitus and healthy controls.RSC advances · 2019Article
- The Relationship between Plasma Taurine Levels and Diabetic Complications in Patients with Type 2 Diabetes Mellitus.Biomolecules · 2019Article
- Effects and Mechanisms of Taurine as a Therapeutic Agent.Biomolecules & therapeutics · 2018Review
- Diabetes-Induced Reactive Oxygen Species: Mechanism of Their Generation and Role in Renal Injury.Journal of diabetes research · 2017Review
- Identification of cysteinylated transthyretin, a predictive biomarker of treatment response to partially hydrolyzed guar gum in type 2 diabetes rats, by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.Journal of clinical biochemistry and nutrition · 2016Article
- Apelin promotes diabetic nephropathy by inducing podocyte dysfunction via inhibiting proteasome activities.Journal of cellular and molecular medicine · 2015Article
- Influence of protein kinase C (PKC) on the prognosis of diabetic nephropathy patients.International journal of clinical and experimental pathology · 2015Article
- Investigation of the Role of a Supplementation with Taurine on the Effects of Hypoglycemic-Hypotensive Therapy Against Diabetes-Induced Nephrotoxicity in Rats.Advances in experimental medicine and biologyArticle
- Ameliorative effect of taurine against diabetes and renal-associated disorders (Review).Medicine internationalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The overexpression of vascular endothelial growth factor (VEGF) is known to be involved in the pathogenesis of diabetic nephropathy. In this study, the protective effects of taurine on diabetic nephropathy along with its underlying mechanism were investigated. Experimental animals were divided into three groups: LETO rats as normal group (n = 10), OLETF rats as diabetic control group (n = 10), and OLETF rats treated with taurine group (n = 10). We treated taurine (200 mg/kg/day) for 20 weeks and treated high glucose (HG, 30 mM) with or without taurine (30 mM) in mouse cultured podocyte. After taurine treatment, blood glucose level was decreased and insulin secretion was increased. Taurine significantly reduced albuminuria and ACR. Also it decreased glomerular volume, GBM thickness and increased open slit pore density through decreased VEGF and increased nephrin mRNA expressions in renal cortex. The antioxidant effects of taurine were confirmed by the reduction of urine MDA in taurine treated diabetic group. Also reactive oxygen species (ROS) levels were decreased in HG condition with taurine treated podocytes compared to without taurine. These results indicate that taurine lowers glucose level via increased insulin secretion and ameliorates the progression of diabetic nephropathy through antifibrotic and antioxidant effects in type 2 diabetes rat model.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.